TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06439485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by PO and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by PO and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by PO and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by PO and IV
Study: NCT05081518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - capsule
Study: NCT05044013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full access to JomPrEP app
Description: All participants will receive the JomPrEP app with access to all of its features which include: customizable page (using avatars and pseudonyms); visual dashboard (track and visualize progress); HIV testing plan (create plan for HIV testing, order self-testing kits, testing site locator); PrEP Care Plan (PrEPxpress, automated reminders for follow-up care, labs, delivery); chat function and discussion forum; tailored messages and reminders; assessment center (weekly assessment on adherence to PrEP, HIV risk, mood); knowledge center (resources on HIV testing and PrEP); Mental health support (screen for P/SUD, counseling feedback, referral to support services); Integration of provider locator (provides users with a GPS enabled map for PrEP and mental health support providers in Malaysia) and Gamification (offers extrinsic motivation by rewarding points/milestones for doing activities within the app). Participants can also contact the RA using the chat function for support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inactivated JomPrEP app
Description: Only information and resources for PrEP services will be available along with access to risk assessment tools.
Study: NCT06112431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Intervention
Description: Participants randomized to the Patient Navigator Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide support with scheduling an in-office eye exams at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Each referred participant will receive several calls from a Patient Navigator over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office eye exam appointments.
Study: NCT05417750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL therapy
Description: A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL therapy
Description: A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL therapy
Description: A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL therapy
Description: A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
Study: NCT05112601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and/or blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and/or blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study: NCT05795569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric Tube removal during extubation
Description: The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Yale Swallow Protocol
Description: The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor).
Study: NCT05205044

Intervention type: DIAGNOSTIC_TEST
Intervention: Apelin-13, Apelin-36
Description: Serum levels of Apelin-13 and Apelin-36

Intervention type: DIAGNOSTIC_TEST
Intervention: Apelin-13, Apelin-36
Description: Serum levels of Apelin-13 and Apelin-36
Study: NCT04912050

Intervention type: DEVICE
Intervention: Tablo Hemodialysis System
Description: Renal Replacement Therapy between 12\< to ≤ 24 hours.
Study: NCT06074211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety in Seconds mobile app: Safe Sleep Education
Description: The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety in Seconds mobile app: Car Seat Safety Education
Description: The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
Study: NCT06432920

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ResWave
Description: Prototype wearable in-phase chest wall vibration device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResWave
Description: Prototype wearable in-phase chest wall vibration device
Study: NCT05795569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classif Nasogastric Tube Management
Description: The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Classic swallowing test
Description: Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it.
Study: NCT04691453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QM-C Hysterectomy
Description: This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QM-B Hysterectomy
Description: Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
Study: NCT05867745

Intervention type: OTHER
Intervention: Interview
Description: As previously specified

Intervention type: OTHER
Intervention: Interview
Description: As previously specified

Intervention type: OTHER
Intervention: Survey
Description: As previously specified

Intervention type: OTHER
Intervention: Survey
Description: As previously specified

Intervention type: OTHER
Intervention: Survey
Description: As previously specified

Intervention type: OTHER
Intervention: Letter to a friend (autoethnography)
Description: As previously specified

Intervention type: OTHER
Intervention: Letter to a friend (autoethnography)
Description: As previously specified
Study: NCT05225766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: used for peripheral block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: used for peripheral block
Study: NCT05163600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blod flow restriction training
Description: includes one strength and one endurance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blod flow restriction training
Description: includes one strength and one endurance training
Study: NCT04997811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate, Bezafibrate, Medroxyprogesterone
Description: Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
Study: NCT05181683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab+Imdevimab
Description: Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab+Imdevimab
Description: Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
Study: NCT05881746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anatomical liver resection
Description: Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
Study: NCT05554094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
Study: NCT05444192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM insoles
Description: computer-aided-design computer-aided-manufacture (CAD/CAM) insoles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM insoles
Description: computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
Study: NCT05881746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonanatomical liver resection
Description: Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
Study: NCT04951986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampicin up to 35 mg/kg/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight \>50 kg) daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin, Pyrazinamide, Ethambutol and Isoniazid
Description: Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
Study: NCT05508334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC88
Description: Every 2 weeks for a maximum of 2 years
Study: NCT06240741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ge/68Ga Generator
Description: Radionuclide generator
Study: NCT05266339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education training
Description: The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
Study: NCT04951986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin, Pyrazinamide, Ethambutol and Isoniazid
Description: Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1.5mg/kg/day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to Prednisone
Study: NCT06633198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Heting
Description: The lower limbs will be immersed in warm (42C) circulating water for 60 minutes.
Study: NCT05266339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard exercise program
Description: The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise program
Description: The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
Study: NCT05583136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parietal tACS combined with visuo-attentional training
Description: Parietal tACS combined with visuo-attentional training
Study: NCT06334666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encourage using pedometer
Description: MASLD patient used pedometer recording actively with encourage by care provider or investigator
Study: NCT06164704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verekitug (UPB-101)
Description: Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Verekitug (UPB-101) matching placebo
Study: NCT05033353

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of regional cerebral oxygenation
Description: Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of regional cerebral oxygenation
Description: Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
Study: NCT05583136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham (placebo) tACS combined with visuo-attentional training
Description: Sham (placebo) tACS combined with visuo-attentional training
Study: NCT05933395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Study: NCT04543903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT05030493

Intervention type: DRUG
Intervention: mFOLFOX6 + panitumumab combination therapy
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

Intervention type: DRUG
Intervention: mFOLFOX6 + bevacizumab combination therapy
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT05237466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECLAIM: Reducing Clutter and Increasing Meaning
Description: Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
Study: NCT06436066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Applications include the following parameters;~1. Patient Information Form (before and after application)~2. Neuropathic Pain Questionnaire - DN4 (before and after application)~3. Neuropathic Pain Questionnaire - Short Form (before and after application)~4. Providing self-acupressure training (before application)~5. Delivery of the self-acupressure training booklet (before application)~6. Sending weekly reminder messages (during implementation)~7. Calling the patient for a check-up after 3 months and re-evaluating with the same scales (After the application)~8. Self-Acupressure - Satisfaction Evaluation Form with Visual Analogue Scale (After application)
Study: NCT05237466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sorting Practice
Description: Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
Study: NCT06522061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stream™ Platform
Description: Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.
Study: NCT03569553

Intervention type: DRUG
Intervention: AIGIV
Description: Anthrax Immune Globulin Intravenous (Human)
Study: NCT05458518

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean wound dressing removal
Description: The cesarean wound dressing is to be removed and the surgical wound exposed
Study: NCT05583136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham (placebo) tACS combined with phonics training
Description: Sham (placebo) tACS combined with phonics training
Study: NCT06462118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
Study: NCT05458518

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cesarean wound dressing removal
Description: The cesarean wound dressing is to be removed and the surgical wound exposed